2Karlawish J. Alzheimer's disease-clinical trials and the logic of clinical purpose[J].New Engl J Med,2006 ;355 ( 15 ) : 1604-6. 被引量：1
3Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study[J].Lancet ,2005 ;366:2112-7. 被引量：1
4Zhang ZX, Zahner GE, Roman GC, et al. Sociodemoga'aphic variation of dementia subtypes in China: methodology and results of a prevalence study in Beijing, Chengdu, Shanghai and Xian [J].Neuroepidemiology, 2006 ;27 (4) : 177-87. 被引量：1
5Prigerson HG. Costs to society of family caregiving for patients with end- stage Alzheimer's disease[J].New Engl J Med,2003 ;349(20) :1891-2. 被引量：1
6Wise J. Scientists call for more funding for research into Alzheimer's dis- ease[J]. BMJ ( Clinical research. ) ,2009 ;338 :b1183. 被引量：1
7Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagno- sis of Alzheimer's disease: revising the NINCDS-ADRDA criteria[J]. Lancet, 2007 ; 6:734 46. 被引量：1
8Chu LW, Chiu KC, Hui SL,et al. The reliability and validity of the Alzhe- imer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) amongthe elderly Chinese in Hong Kong[J].Ann Acad Med Singapore,2000; 29:424-85. 被引量：1
9Thai LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer's disease [J]. Alzheimer Dis Assoc Disord, 2006 ; 20 (1) :6-15. 被引量：1
10Cacabelos R. The application of functional genomics to Alzheimer's dis- ease [J].Pharmcaogenomics ,2003 ;4 ( 5 ) : 597-621. 被引量：1
二级参考文献21
1Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med, 2003, 138: 400-410. 被引量：1
2Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer′s amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286:735-741. 被引量：1
3Esler WP, Kimberly WT, Ostaszewski BL, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol, 2000, 2: 428-434. 被引量：1
4Li YM, Xu M, Lai MT, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature, 2000, 405: 689-694. 被引量：1
5De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 1998, 391:387-390. 被引量：1
6Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem, 1994, 269: 17386-17389. 被引量：1
7Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer′s disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo. Neuron, 1996, 17: 1005-1013. 被引量：1
8Xia W, Zhang J, Perez R, et al. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci U S A, 1997, 94: 8208-8213. 被引量：1
9Thinakaran G, Borchelt DR, Lee MK, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron, 1996, 17:181-190. 被引量：1
10Kimberly WT, Xia W, Rahmati T, et al. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem, 2000, 275: 3173-3178. 被引量：1
